A novel inhibitor of Rho GDP-dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma.

Molecular-targeted therapies are considered a promising strategy for the treatment of most types of human cancer. Rho GDP-dissociation inhibitor α (RhoGDIα), which functions mainly by controlling the cellular distribution and activity of Rho GTPases and is associated with tumor progression and poor prognosis of cancer patients, has become a new promising target for anticancer treatment. Recently, a specific RhoGDIα inhibitor (no.

Plasmid-encoding vasostatin inhibited the growth and metastasis of human hepatocellular carcinoma cells.

The growth and metastasis of solid tumors depends on angiogenesis. Anti-angiogenesis therapy may represent a promising therapeutic option. Vasostatin, the N-terminal domain of calreticulin, is a very potent endogenous inhibitor of angiogenesis and tumor growth.

[Correlation between FDG PET /CT and the expression of glutl and ki-67 antigen in esophageal cancer].

Objective: To evaluate the correlation between standardized uptake valus (SUV) of 18F-fluorodeoxyglucose (18 F-FDG) of tumor at PET/CT examination and the expression of glucose transporter-1 (Glutl) and Ki-67 in esophageal cancer.

Methods: 56 patients with esophageal cancer were evaluated with 18 F-FDG PET/CT examination before operation. The expression of Glut1 and Ki-67 antigen in the tumor tissues was detected by immunohistochemistry after operation.

[The effects of vascular endothelial growth factor on dendritic cells in esophageal tumor tissue].

Aim: To investigate the relationship between vascular endothelial growth factor (VEGF) and S100 protein positive dendritic cell (DC) in esophagelal tumor tissue.

Methods: VEGF and S100 protein in 94 patients with esophageal carcinoma were detected by HRP Labelled streptavidin biotin(LSAB) immunohistochemical method.

Results: Postive rate of VEGF in esophageal tumor tissues was 74.